Evidence map›Paper›PMID 34362900›Full record

ArticleNature communications2021

MAIT cells regulate NK cell-mediated tumor immunity.

Emma V Petley, Hui-Fern Koay, Melissa A Henderson, Kevin Sek, Kirsten L Todd, Simon P Keam, Junyun Lai, Imran G House, Jasmine Li, Magnus Zethoven and 21 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 94 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Avoidance of MAIT cells is an essential determinant ofProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Acetoacetate suppresses colon cancer via an MR1-MAIT axis.bioRxiv : the preprint server for biology · 2025
    Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 3 institutions in 2 countries.

Emma V PetleyCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Hui-Fern KoayDepartment of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-3236-9609
Melissa A HendersonCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Kevin SekCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-4634-7600
Kirsten L ToddCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Simon P KeamCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Junyun LaiCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Imran G HouseCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-6245-5954
Jasmine LiCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Magnus ZethovenSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
Amanda X Y ChenCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Amanda J OliverCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Jessica MichieCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Andrew J FreemanCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-0040-5617
Lauren GiuffridaCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Jack D ChanCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-5942-8592
Angela PizzollaCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-2024-4144
Jeffrey Y W MakInstitute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0002-8011-4539
Timothy R McCullochUniversity of Queensland Diamantina Institute, The University of Queensland, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0003-0247-7374
Fernando Souza-Fonseca-GuimaraesUniversity of Queensland Diamantina Institute, The University of Queensland, Brisbane, QLD, Australia.
Conor J KearneyCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Rosemary MillenCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Robert G RamsayCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Nicholas D HuntingtonDepartment of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-5267-7211
James McCluskeyDepartment of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-8597-815X
Jane OliaroCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-2097-6428
David P FairlieInstitute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0002-7856-8566
Paul J NeesonCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-2729-5887
Dale I Godfrey *Department of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia. godfrey@unimelb.edu.au.ORCID http://orcid.org/0000-0002-3009-5472
Paul A Beavis *Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. paul.beavis@petermac.org.ORCID http://orcid.org/0000-0002-2116-013X
Phillip K Darcy *Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. phil.darcy@petermac.org.ORCID http://orcid.org/0000-0002-5303-9561
The University of Melbourne · AUAustralian Research Council · AUThe University of Queensland · AU

Funding

Investigating the basis of MAIT cell antigen potencyR01AI148407 · NIAID · UNIVERSITY OF MELBOURNE · PI MCCLUSKEY, JAMES · 2020 to 2024
$2.7M
NIAID NIH HHS R01 AI148407
6 · The paper itself

Abstract

The function of MR1-restricted mucosal-associated invariant T (MAIT) cells in tumor immunity is unclear. Here we show that MAIT cell-deficient mice have enhanced NK cell-dependent control of metastatic B16F10 tumor growth relative to control mice. Analyses of this interplay in human tumor samples reveal that high expression of a MAIT cell gene signature negatively impacts the prognostic significance of NK cells. Paradoxically, pre-pulsing tumors with MAIT cell antigens, or activating MAIT cells in vivo, enhances anti-tumor immunity in B16F10 and E0771 mouse tumor models, including in the context of established metastasis. These effects are associated with enhanced NK cell responses and increased expression of both IFN-γ-dependent and inflammatory genes in NK cells. Importantly, activated human MAIT cells also promote the function of NK cells isolated from patient tumor samples. Our results thus describe an activation-dependent, MAIT cell-mediated regulation of NK cells, and suggest a potential therapeutic avenue for cancer treatment.

Indexed as

Immunity, CellularAnimalsAntineoplastic AgentsCell Line, TumorCytokinesHistocompatibility Antigens Class IHumansImmunityKiller Cells, NaturalMiceMice, Inbred C57BLMice, KnockoutMinor Histocompatibility AntigensMucosal-Associated Invariant T CellsNeoplasm MetastasisNeoplasmsAntineoplastic AgentsCytokinesHistocompatibility Antigens Class IMinor Histocompatibility AntigensMr1 protein, mouse

Identifiers

PMID34362900
PMCPMC8346465
OpenAlexW3123212121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.